105 related articles for article (PubMed ID: 23890770)
1. Letter to the editor - author's response.
van de Water W; Fontein DB; van de Velde CJ
Eur J Cancer; 2013 Oct; 49(15):3378-9. PubMed ID: 23890770
[No Abstract] [Full Text] [Related]
2. Upfront adjuvant aromatase inhibitors in women with lobular breast cancer.
Montemurro F
Eur J Cancer; 2013 Oct; 49(15):3376-7. PubMed ID: 23867125
[No Abstract] [Full Text] [Related]
3. Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.
van de Water W; Fontein DB; van Nes JG; Bartlett JM; Hille ET; Putter H; Robson T; Liefers GJ; Roumen RM; Seynaeve C; Dirix LY; Paridaens R; Kranenbarg EM; Nortier JW; van de Velde CJ
Eur J Cancer; 2013 Jan; 49(2):297-304. PubMed ID: 22954666
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting angiogenesis in breast cancer: the beginning of the end or the end of the beginning?
Rugo HS
J Clin Oncol; 2012 Mar; 30(9):898-901. PubMed ID: 22331930
[No Abstract] [Full Text] [Related]
5. Different adjuvant chemotherapy regimens in older breast cancer patients?
Wildiers H; Brain E
Ann Oncol; 2015 Apr; 26(4):613-615. PubMed ID: 25600566
[No Abstract] [Full Text] [Related]
6. Different outcome variables yield different results!
Brouckaert O; Wildiers H; Neven P
Ann Oncol; 2013 Feb; 24(2):554. PubMed ID: 23277485
[No Abstract] [Full Text] [Related]
7. De-escalation attempts for adjuvant trastuzumab: longer beats shorter.
Curigliano G; Goldhirsch A
Ann Oncol; 2015 Jul; 26(7):1275-6. PubMed ID: 26002609
[No Abstract] [Full Text] [Related]
8. Reply to 'Different outcome variables yield different results', by O. Brouckaert et al.
Truin W; Voogd AC; Roumen RMH
Ann Oncol; 2013 Feb; 24(2):555. PubMed ID: 23341480
[No Abstract] [Full Text] [Related]
9. Inflammatory breast cancer after neoadjuvant chemotherapy: can magnetic resonance imaging precisely diagnose the final pathological response?
Chen JH; Mehta RS; Nalcioglu O; Su MY
Ann Surg Oncol; 2008 Dec; 15(12):3609-13. PubMed ID: 18807091
[No Abstract] [Full Text] [Related]
10. [Response evaluation with mammography and ultrasound].
Junkermann H; Schmid H; Sinn HP; Wallwiener D
Zentralbl Gynakol; 1996; 118(10):572-3. PubMed ID: 8999712
[No Abstract] [Full Text] [Related]
11. [Effects of neoadjuvant chemotherapy on estrogen and progesterone receptors and HER-2 in breast cancer].
Zhao J; Wu YL; Wang YD; Zhao GR; Wang J
Di Yi Jun Yi Da Xue Xue Bao; 2004 Dec; 24(12):1437-9. PubMed ID: 15604081
[TBL] [Abstract][Full Text] [Related]
12. FOXA1 Expression Significantly Predict Response to Chemotherapy in Estrogen Receptor-Positive Breast Cancer Patients.
Xu C; Wei Q; Guo J; Zhou JC; Mei J; Jiang ZN; Shen JG; Wang LB
Ann Surg Oncol; 2015; 22(6):2034-9. PubMed ID: 25707489
[TBL] [Abstract][Full Text] [Related]
13. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer.
Truin W; Vugts G; Roumen RM; Maaskant-Braat AJ; Nieuwenhuijzen GA; van der Heiden-van der Loo M; Tjan-Heijnen VC; Voogd AC
Ann Surg Oncol; 2016 Jan; 23(1):51-7. PubMed ID: 25980321
[TBL] [Abstract][Full Text] [Related]
14. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
15. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
16. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial.
Bernsdorf M; Ingvar C; Jörgensen L; Tuxen MK; Jakobsen EH; Saetersdal A; Kimper-Karl ML; Kroman N; Balslev E; Ejlertsen B
Breast Cancer Res Treat; 2011 Apr; 126(2):463-70. PubMed ID: 21234672
[TBL] [Abstract][Full Text] [Related]
17. Hand-foot syndrome in breast cancer patients receiving adjuvant chemotherapy.
Lee CK; Lynch J
Intern Med J; 2007 Apr; 37(4):281-2. PubMed ID: 17388876
[No Abstract] [Full Text] [Related]
18. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
Wenzel C; Bartsch R; Hussian D; Pluschnig U; Altorjai G; Zielinski CC; Lang A; Haid A; Jakesz R; Gnant M; Steger GG
Breast Cancer Res Treat; 2007 Jul; 104(1):109-14. PubMed ID: 17061042
[TBL] [Abstract][Full Text] [Related]
19. Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.
Alramadhan M; Ryu JM; Rayzah M; Nam SJ; Kim SW; Yu J; Lee SK; Bae SY; Park S; Paik HJ; Lee JE
Breast; 2016 Dec; 30():111-117. PubMed ID: 27697675
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]